Patient satisfaction after conversion from warfarin to direct oral anticoagulants for patients on extended duration of anticoagulation for venous thromboembolism – The SWAN Study

Hendriks, Thomas; McGregor, Scott; Rakesh, Shilpa; Robinson, Julie Ann; Ho, Kwok M.; Baker, Ross

doi:10.1371/journal.pone.0234048

Cited by 13 publications

(10 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The burdens and benefits subscale scores were comparable with previous studies for rivaroxaban for the treatment of VTE (Table 6). Existing data are predominantly from the clinical trial setting, with the exception of Hendriks and colleagues in Australia 44 . Greater patient‐reported treatment burdens were found to be predictive of nonadherence showing the important relationship of patient satisfaction and medication adherence.…”

Section: Discussionmentioning

confidence: 98%

Adherence to rivaroxaban for the treatment of venous thromboembolism–Results from the FIRST registry

Speed

Auyeung

Patel

et al. 2021

Research and Practice in Thrombosis and Haemostasis

View full text Add to dashboard Cite

Background: Medication nonadherence can result in poor clinical outcomes and significant costs to health care providers. When treating venous thromboembolism (VTE), subtherapeutic anticoagulation may contribute to complications such as recurrent VTE or postthrombotic syndrome. Objectives: To describe the extent, reasons for, and predictors of nonadherence to rivaroxaban for the treatment of VTE in clinical practice in the United Kingdom reported by participants of the FIRST registry. Patients/Methods: The FIRST registry was an observational, multicenter registry reporting on the use of rivaroxaban in routine clinical practice. FIRST registry participants completed an adherence screening questionnaire during their treatment and follow-up.Results: In total, 1028 participants completed 1660 questionnaires over 2 years. One hundred thirteen of 1028 (11%) reported nonadherence at 28 days (interquartile range, 21-45). Reasons given for nonadherence at 1 month were forgetfulness (8.6% vs 74.7%; P < .001), carelessness (2.7% vs 27.3%; P < .001) or a change in routine (7.4% vs 25.5%; P < .001) reported by adherent and nonadherent participants, respectively.

show abstract

Section: Discussionmentioning

confidence: 98%

Adherence to rivaroxaban for the treatment of venous thromboembolism–Results from the FIRST registry

Speed

Auyeung

Patel

et al. 2021

Research and Practice in Thrombosis and Haemostasis

View full text Add to dashboard Cite

show abstract

“…Patients in our study receiving warfarin as their anticoagulant were less likely to be satisfied with their care, however our study was not designed to probe additional details regarding specific anticoagulant therapy. Published studies examining satisfaction of patients receiving warfarin versus DOACs have shown those receiving warfarin are less satisfied with their anticoagulant therapy [ 8 , 9 , 18 ], particularly if they have switched from warfarin to a DOAC [ 8 ]. Improved patient convenience, reduced frequency of medical contact, and fewer side effects have been noted as reasons why patients are more satisfied with DOACS [ 8 ].…”

Section: Discussionmentioning

confidence: 99%

“…Published studies examining satisfaction of patients receiving warfarin versus DOACs have shown those receiving warfarin are less satisfied with their anticoagulant therapy [ 8 , 9 , 18 ], particularly if they have switched from warfarin to a DOAC [ 8 ]. Improved patient convenience, reduced frequency of medical contact, and fewer side effects have been noted as reasons why patients are more satisfied with DOACS [ 8 ].…”

Section: Discussionmentioning

confidence: 99%

Patient satisfaction with quality of care of a multidisciplinary thrombosis service – a cross sectional survey

Young

Bonsu

Lee

et al. 2022

BMC Health Serv Res

View full text Add to dashboard Cite

Background In October 2017 we opened a multidisciplinary Adult Outpatient Thrombosis Service (Thrombosis Service) in a regional health authority servicing over 300 000 people. The Thrombosis Service is a comprehensive thrombosis and anticoagulation management program with unique, interrelated clinics providing a broad spectrum of care for this patient group. Evaluation of patient satisfaction with this new model of patient care is an important quality measurement. Methods We conducted a cross-sectional survey of patients who attended the Thrombosis Service between October 2017 and May 2019. We measured patient satisfaction with the seven-item Short Assessment of Patient Satisfaction (SAPS) which uses a 5 point scale (0–4) for responses. The continuous score range for SAPS is 0 to 28. Categorical responses for SAPS are defined as 0–10 very dissatisfied, 11–18 dissatisfied, 19–26 satisfied, and 27–28 very satisfied. We used linear regression analysis to examine the associations between patients’ characteristics and their satisfaction with the Thrombosis Service. Results Of the 1058 surveys distributed, 563 were returned. The mean score for the SAPS was 22.1 (SD 4.1, range 8 to 28). For the categorical response, 85% were satisfied or very satisfied with the Thrombosis Service. The multivariate analysis showed patients with post-secondary education were more satisfied with the Thrombosis Service (β-coefficient 1.6153, p = 0.024), and patients taking warfarin were less likely to be satisfied with the Thrombosis Service (β-coefficient -1.5832, p = 0.0390). Conclusions The majority of survey participants (85%) who attended an appointment in one of the Thrombosis Service clinics were satisfied or very satisfied with the care they received. This information may benefit other centres who are interested in developing a program to manage thrombosis and anticoagulation.

show abstract

“…The majority of current evidence is based on warfarin era data where delivery of anticoagulation was difficult and associated with a higher risk of bleeding relative to the direct oral anticoagulant (DOAC) era [7,8]. Furthermore DOACs are associated with increased patient acceptability in comparison to warfarin [9,10]. Adherence rates for DOACs are significantly higher [11,12] along with more stable pharmacokinetics than warfarin of which in one large population study only 41% of patients were within therapeutic range ≥65% of the time [13].…”

Section: Introductionmentioning

confidence: 99%

Isolated Distal Deep Vein Thrombosis in the Direct Oral Anticoagulant (DOAC) Era – Should Our Management Change?

Brook¹,

Lim²,

HO³

2022

WJCMR

View full text Add to dashboard Cite

Objectives: There remains no consensus management for isolated distal deep vein thrombosis (IDDVT), with current data inconclusive and dating back to the warfarin era. In the current direct oral anticoagulant (DOAC) era, optimal management of IDDVT needs to be re-assessed. Methods: A retrospective evaluation of patients treated with therapeutic anticoagulation for IDDVT in the DOAC era (2013-2016) was compared with historically published data from the warfarin era (2011)(2012). Results: 247 patients were evaluated, 103 from the DOAC era and 122 from the warfarin era. There were less provoked events in the DOAC cohort (45.6% vs 66.7%, p=<0.01). Overall rate of major bleeding was 1.6% with 1.0% in the DOAC era and 2.1% in the warfarin era (p=0.50). There was no difference in rates of VTE progression on treatment 5.8% vs 4.9% respectively (p=0.91). Overall risk of VTE recurrence post cessation was 5.3% (1.86 per 100 person years) with no difference between groups (5.8% vs 4.9%, p=0.74). Conclusions: Our data shows IDDVT is not always benign, with risk of extension despite treatment and long-term risk of VTE-recurrence. Therapeutic anticoagulation with DOAC in these patients was associated with a major bleeding rate of 1.0% in the DOAC cohort. Further clinical trials into the optimal IDDVT management in the DOAC era are necessary.

show abstract

Patient satisfaction after conversion from warfarin to direct oral anticoagulants for patients on extended duration of anticoagulation for venous thromboembolism – The SWAN Study

Cited by 13 publications

References 22 publications

Adherence to rivaroxaban for the treatment of venous thromboembolism–Results from the FIRST registry

Adherence to rivaroxaban for the treatment of venous thromboembolism–Results from the FIRST registry

Patient satisfaction with quality of care of a multidisciplinary thrombosis service – a cross sectional survey

Isolated Distal Deep Vein Thrombosis in the Direct Oral Anticoagulant (DOAC) Era – Should Our Management Change?

Contact Info

Product

Resources

About